Israel Active

Scientists at Israel’s Weizmann Institute have developed algorithms that can identify structural variants in the genomes of human gut microbiomes. People with a certain variant were much thinner than those who had the same microbe but not the variant. The variants can also pinpoint disease factors.

Israel’s Technion Institute has set up a 3D center for the printing of cells, tissues and organs. Its purpose is to enable Technion researchers to develop tissues containing blood vessels or 3D scaffolds that quickly connect to the patient’s own blood vessels.

Researchers at Israel's Ben Gurion University have created tiny robots that could soon become part of medical procedures.

I reported previously on Jerusalem-based immunotherapy company Enlivex Therapeutics. Enlivex has merged with Tel Aviv-headquartered Bioblast , which is developing treatments for rare genetic diseases.

During the winter, Israeli charity Ezer Mizion often takes oncology clinic kids on a trip to Mt. Hermon. And if their blood count results are anything to go by, the benefits to the children last long after they return from the “sledging, tobogganing and fun, fun, fun!”

Israel’s Sheba hospital is partnering with Switzerland’s Lonza Group to fast-track production of the CAR-T cancer immunotherapy invented by Israeli scientists. Sheba is the first hospital to trial and refine Lonza’s Cocoon manufacturing platform for growing cells to treat hundreds of oncology patients.

Israel’s Ibex Medical Analytics develops a diagnostic system that uses computer vision, machine learning, and electronic medical records to confirm cancer diagnoses of tissue biopsies. Ibex’s technology helps minimize the risk of misdiagnosis. Ibex has just received $11 million of funding.

I reported previously on Israel’s HIL Applied Medical and its focused proton beam lasers to treat tumors.  HIL is spending $5 million to set-up a research and development and manufacturing center at the Hebrew University of Jerusalem.

Israel’s Teva has launched a generic version of EXJADE (deferasirox) in the US. It treats patients two years of age and older for chronic iron overload due to blood transfusions. Currently, one in eight generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Israel’s HeraMED is partnering with Israeli-owned device manufacturer Quasar to mass-produce its HeraBEAT ultrasound smartphone-based fetal heartbeat monitor in Shenzhen, China. HeraBEAT uses amplified ultrasound doppler technology.